Jennifer Volkman

453 total citations
9 papers, 365 citations indexed

About

Jennifer Volkman is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jennifer Volkman has authored 9 papers receiving a total of 365 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 4 papers in Molecular Biology and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jennifer Volkman's work include Cancer Treatment and Pharmacology (4 papers), Cancer therapeutics and mechanisms (3 papers) and Microtubule and mitosis dynamics (2 papers). Jennifer Volkman is often cited by papers focused on Cancer Treatment and Pharmacology (4 papers), Cancer therapeutics and mechanisms (3 papers) and Microtubule and mitosis dynamics (2 papers). Jennifer Volkman collaborates with scholars based in United States, Spain and Netherlands. Jennifer Volkman's co-authors include George Wilding, Dona Alberti, Rebecca Marnocha, Jill Kolesar, Rhoda Arzoomanian, Kendra D. Tutsch, Kim Binger, Lynn Van Ummersen, James P. Thomas and Jens C. Eickhoff and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Cancer Chemotherapy and Pharmacology.

In The Last Decade

Jennifer Volkman

9 papers receiving 356 citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Jennifer Volkman	239	111	91	62	57	9	365
Stacy M. Plum	200 0.8×	104 0.9×	78 0.9×	35 0.6×	76 1.3×	10	348
Oisun Jung	250 1.0×	113 1.0×	192 2.1×	83 1.3×	57 1.0×	15	410
Jeffrey E. Lehr	308 1.3×	169 1.5×	42 0.5×	65 1.0×	70 1.2×	9	494
Kenichiro Naito	296 1.2×	96 0.9×	51 0.6×	32 0.5×	129 2.3×	14	386
Kirsty Ratcliffe	243 1.0×	123 1.1×	44 0.5×	35 0.6×	77 1.4×	7	385
Jennie Hauser	332 1.4×	235 2.1×	60 0.7×	62 1.0×	94 1.6×	13	542
Jan‐Patrik Wiksten	390 1.6×	213 1.9×	127 1.4×	45 0.7×	154 2.7×	10	646
Brigitte Bisarò	307 1.3×	172 1.5×	109 1.2×	161 2.6×	103 1.8×	16	513
Yveline Bourgeois	223 0.9×	90 0.8×	61 0.7×	24 0.4×	55 1.0×	8	303
Ruth J. Muschel	333 1.4×	247 2.2×	60 0.7×	26 0.4×	176 3.1×	8	517

Countries citing papers authored by Jennifer Volkman

Since Specialization

Citations

This map shows the geographic impact of Jennifer Volkman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer Volkman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer Volkman more than expected).

Fields of papers citing papers by Jennifer Volkman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jennifer Volkman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer Volkman. The network helps show where Jennifer Volkman may publish in the future.

Co-authorship network of co-authors of Jennifer Volkman

This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer Volkman. A scholar is included among the top collaborators of Jennifer Volkman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer Volkman. Jennifer Volkman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Holen, Kyle D., Chandra P. Belani, George Wilding, et al.. (2010). A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose. Cancer Chemotherapy and Pharmacology. 67(2). 447–454. 60 indexed citations

Dubey, Sarita, Paul R. Hutson, Dona Alberti, et al.. (2005). Phase I study of docetaxel and topotecan in patients with advanced malignancies. Journal of Oncology Pharmacy Practice. 11(4). 132–138. 2 indexed citations

McNeel, Douglas G., Jens C. Eickhoff, Fred T. Lee, et al.. (2005). Phase I Trial of a Monoclonal Antibody Specific for αvβ3 Integrin (MEDI-522) in Patients with Advanced Malignancies, Including an Assessment of Effect on Tumor Perfusion. Clinical Cancer Research. 11(21). 7851–7860. 121 indexed citations

Holen, Kyle D., Eric K. Rowinsky, George Wilding, et al.. (2004). Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV Q 21 days. Journal of Clinical Oncology. 22(14_suppl). 2078–2078. 28 indexed citations

Ummersen, Lynn Van, Kim Binger, Jennifer Volkman, et al.. (2004). A Phase I Trial of Perifosine (NSC 639966) on a Loading Dose/Maintenance Dose Schedule in Patients with Advanced Cancer. Clinical Cancer Research. 10(22). 7450–7456. 126 indexed citations

Liu, Glenn, Howard H. Bailey, Rhoda Arzoomanian, et al.. (2003). Gemcitabine, Paclitaxel, and Piritrexim. American Journal of Clinical Oncology. 26(3). 280–284. 3 indexed citations

Dubey, Sarita, Michael N. Gould, Kendra D. Tutsch, et al.. (2003). Phase I trial of perillyl alcohol administered four times daily continuously. Cancer Chemotherapy and Pharmacology. 52(5). 361–366. 21 indexed citations

Liu, Glenn, Howard H. Bailey, Rhoda Arzoomanian, et al.. (2003). . American Journal of Clinical Oncology. 26(3). 280–284. 2 indexed citations

Thomas, James P., Daniel Mulkerin, Jordan Berlin, et al.. (2002). Phase I Study of Eniluracil, Oral 5-Fluororacil and Gemcitabine in Patients with Advanced Malignancy. Investigational New Drugs. 20(4). 377–382. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact